School of Biomedical Engineering, Bio-ID Center, Shanghai Jiao Tong University, Shanghai 200240, China.
Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200240, China.
Dis Markers. 2019 Feb 5;2019:4108474. doi: 10.1155/2019/4108474. eCollection 2019.
As a noninvasive blood testing, the detection of cell-free DNA (cfDNA) methylation in plasma has raised an increasing interest due to diagnostic applications. Although extensively used in cfDNA methylation analysis, bisulfite sequencing is less cost-effective. In this study, we investigated the cfDNA methylation patterns in lung cancer patients by MeDIP-seq. Compared with the healthy individuals, 330 differentially methylated regions (DMRs) at gene promoters were identified in lung cancer patients with 33 hypermethylated and 297 hypomethylated regions, respectively. Moreover, these hypermethylated genes were validated with the publicly available DNA methylation data, yielding a set of ten significant differentially methylated genes in lung cancer, including , , , , , , , , , and -3. Our study demonstrated MeDIP-seq could be effectively used for cfDNA methylation profiling and identified a set of potential biomarker genes with clinical application for lung cancer.
作为一种非侵入性的血液检测方法，血浆中游离 DNA（cfDNA）甲基化的检测由于其诊断应用而引起了越来越多的关注。尽管亚硫酸氢盐测序在 cfDNA 甲基化分析中得到了广泛应用，但它的成本效益较低。在这项研究中，我们通过 MeDIP-seq 研究了肺癌患者的 cfDNA 甲基化模式。与健康个体相比，肺癌患者中有 330 个基因启动子的差异甲基化区域（DMR），分别有 33 个高甲基化区域和 297 个低甲基化区域。此外，这些高甲基化基因与公开的 DNA 甲基化数据进行了验证，得到了一组在肺癌中具有显著差异甲基化的 10 个基因，包括、、、、、、、、和-3。我们的研究表明，MeDIP-seq 可有效地用于 cfDNA 甲基化分析，并鉴定出一组具有临床应用价值的潜在肺癌生物标志物基因。
